SEC Form 4 · accession 0001179110-16-026300
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Elston
Director
Period of report
Jun 8, 2016
Accepted (ET)
Jun 9, 2016 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 8, 2016 | A | 10,000 | — | A | 28,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F3 | $4.72 | Jun 8, 2016 | A | 15,000 | A | — | Jun 8, 2026 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1On June 8, 2016, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions.
- F2Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
- F3Such option vests in three equal annual installments beginning June 8, 2017.